INmune Bio CEO to Speak at Maxim Growth Summit

Inmune Bio ( (INMB) ) just unveiled an update.

On October 14, 2025, INmune Bio Inc. announced that its CEO, David Moss, will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit in New York City on October 22-23, 2025. During the panel, Moss will discuss the company’s CORDStrom™ platform, which is aimed at treating Recessive Dystrophic Epidermolysis Bullosa, a rare pediatric disease. This participation highlights INmune Bio’s ongoing efforts to position itself as a leader in innovative treatments for rare diseases, potentially impacting its market presence and stakeholder engagement.

The most recent analyst rating on (INMB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company has three main product platforms: Dominant-Negative Tumor Necrosis Factor (DN-TNF) for neutralizing soluble TNF, CORDStrom™ for treating Recessive Dystrophic Epidermolysis Bullosa, and INKmune® for enhancing natural killer cells to fight cancer.

Average Trading Volume: 1,430,746

Technical Sentiment Signal: Sell

Current Market Cap: $49.45M

For detailed information about INMB stock, go to TipRanks’ Stock Analysis page.